Form 4: PROCEPT BioRobotics Director Elisabeth Sandoval Receives Significant Equity Awards

PROCEPT BioRobotics Corp. Director Elisabeth Sandoval was granted 1,538 restricted stock units and 2,771 stock options on June 10, 2025, as disclosed in a recent SEC Form 4 filing.

Summary

• Elisabeth Sandoval, a Director of PROCEPT BioRobotics Corp. (PRCT), was granted equity awards on June 10, 2025.
• She received 1,538 restricted stock units (RSUs), each representing a contingent right to receive one share of Common Stock, granted at a price of $0.
• Additionally, Ms. Sandoval was granted 2,771 stock options with an exercise price of $64.23 per share, also granted at a price of $0.
• Both the RSUs and stock options are subject to vesting in full on the earlier of the one-year anniversary of the grant date or the date of the next annual meeting following the grant date, contingent upon continued service.
• Following these transactions, Ms. Sandoval directly beneficially owns 12,561 shares of Common Stock and 2,771 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The filing indicates a routine equity grant to a director, which is a positive for aligning interests and retaining talent, but it does not contain information that would significantly alter the company's fundamental outlook or financial performance.

Positives

• The granting of equity awards to a director aligns their financial interests with those of shareholders, incentivizing long-term company performance and value creation.
• The vesting conditions, tied to continued service, promote the retention of key board members and ensure their ongoing commitment to the company's success.

Future Outlook

N/A

Industry Context

This Form 4 filing reflects standard compensation practices for directors in the biotechnology and medical device industry, where equity grants are common to align leadership incentives with company performance and shareholder value. Such grants are a routine part of executive and board compensation packages aimed at fostering long-term commitment.

Comparison to Industry Standards

• The granting of restricted stock units and stock options to a director is a common practice in the U.S. public company landscape, particularly within the high-growth biotechnology and medical device sectors.
• This compensation structure is designed to align the director's financial interests with the long-term performance of the company, similar to practices observed at companies like Intuitive Surgical (ISRG) or Medtronic (MDT) for their non-executive directors, though specific grant sizes and vesting schedules vary based on company size, stage, and individual roles.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's interests with shareholders, potentially leading to better long-term decision-making and increased focus on shareholder value.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The granted restricted stock units (RSUs) will vest in full on the earlier of the one-year anniversary of the grant date (June 10, 2026) or the date of the next annual meeting following the grant date, subject to continued service.
• The granted stock options will vest in full on the earlier of the one-year anniversary of the grant date (June 10, 2026) or the date of the next annual meeting following the grant date, subject to continued service.

Key Dates

Keywords

PROCEPT BioRobotics, PRCT, Elisabeth Sandoval, Form 4, SEC Filing, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Equity Grant, Director Compensation, Corporate Governance, Biotechnology, Medical Devices